News | September 22, 2010

Core Curriculum Published for Structural Heart Disease Treatment

September 23, 2010 – The first consensus document for treating structural heart disease has been published by the Society for Cardiovascular Angiography and Interventions (SCAI). The core curriculum and the results of a survey of physicians and training doctors were published Tuesday in Catheterization and Cardiovascular Interventions and JACC Cardiovascular Interventions.

The curriculum, which was endorsed by the American College of Cardiology Foundation and written by interventional specialists from multiple regions, defines training and credentialing requirements along with program standards for practitioners.

Interventional treatments have evolved rapidly during the past decade, and therapies are helping more patients who previously had to undergo open-heart surgery, or who could not be treated at all. With such rapid advancement, SCAI identified a need for uniformity across training programs and specific credentials and standards for practitioners. Currently, a lack of comprehensive training programs prohibits many practitioners from treating structural heart disease, according to the SCAI survey of 107 U.S.-based interventional cardiologists.

"The primary goal of the core curriculum is to provide patients with the highest level of care and treatment available," said Carlos Ruiz, M.D., Ph.D., FSCAI, professor of pediatrics and medicine and director of the division of congenital and structural heart disease at Lenox Hill Heart and Vascular Institute of New York, and lead author of the core curriculum. "The core curriculum will serve training centers and practitioners dedicated to growing their knowledge and skill base for structural heart disease interventions and provide a forum to discuss the latest treatment advancements for structural heart disease to advance and improve patient care."

The curriculum outlines specific training recommendations and skill requirements, including:

• Superb basic catheterization skills with the ability to achieve unusual types of vascular access and manipulate various catheters, balloons and other devices.

• The ability to competently handle potential complications.

• A knowledge base and interventional skills for a variety of complex structural heart diseases, including appropriate device selection, imaging needs, stenting techniques, managing complications and acute and long-term post-procedural care.

"As structural heart disease procedures advance and become increasingly common, it is essential that practitioners acquire the right set of skills and knowledge base," said SCAI Past President Ted Feldman, M.D., FSCAI, director of cardiac catheterization at Evanston Northwestern Healthcare in Evanston, Ill., and chair of the Structural Heart Disease Council. "Patient care will benefit from those who acquire the skills and training outlined in the core curriculum document."

For more information: www.SCAI.org

Related Content

Reducing Secondary Mitral Regurgitation in Heart Failure Does Not Improve Two-year Outcomes
News | Heart Valve Technology | September 11, 2019
Percutaneous reduction of secondary mitral regurgitation in patients with heart failure does not lower death and...
Abbott Launches Pivotal Trial of TriClip Tricuspid Valve Repair System
News | Heart Valve Technology | September 05, 2019
Abbott announced the launch of the company's TRILUMINATE Pivotal trial evaluating the safety and effectiveness of its...
An illustration of the BASILICA procedure showing the leaflet of the original bioprosthetic valve sliced open to allow coronary blood flow after implantation of a TAVR valve. The new TAVR valve can push the leaflets of the bioprosthetic valve upwards, blocking the coronary arteries. During the BASILICA procedure, a catheter directs an electrified guidewire through the base of the left aortic cusp into a snare in the left ventricular outflow tract (LVOT). After snare retrieval, the mid-shaft of the guidewire

An illustration of the BASILICA procedure showing the leaflet of the original bioprosthetic valve sliced open to allow coronary blood flow after implantation of a TAVR valve. The new TAVR valve can push the leaflets of the bioprosthetic valve upwards, blocking the coronary arteries. During the BASILICA procedure, a catheter directs an electrified guidewire through the base of the left aortic cusp into a snare in the left ventricular outflow tract (LVOT). After snare retrieval, the mid-shaft of the guidewire is electrified to lacerate the leaflet, and the the leaflet splays after TAVR permitting coronary flow.

Feature | Heart Valve Technology | August 27, 2019
A novel technique has proven successful in preventing coronary artery obstruction during transcatheter aortic valve r
Edwards Recalls Sapien 3 Ultra Delivery System Due to Burst Balloons During Surgery
News | Heart Valve Technology | August 22, 2019
Edwards Lifesciences is recalling the Sapien 3 Ultra delivery system after receiving reports of burst balloons during...
FDA Approves Sapien 3, CoreValve Evolut TAVR Valves for Low-risk Patients

Left, an illustration of the beginning of deployment for a CoreValve Evolut self-expanding transcatheter aortic replacement (TAVR) valve. Right, an illustration of the final balloon expansion of an Edwards Lifesciences Sapien 3 TAVR valve. Both valves received simultaneous FDA clearance for use in low-risk surgical patients. Clearing this last hurdle now allows wide-spread use of minimally invasive TAVR in all patients who otherwise would need an open-heart surgical valve replacement. 

Feature | Heart Valve Technology | August 16, 2019 | Jeff Zagoudis, Associate Editor, and Dave Fornell, Editor
In one coordinated move, the U.S. Food and Drug Administration (FDA) opened transcatheter aortic valve replacement (...
Abbott Receives U.S. Approval of Next-generation MitraClip G4
Technology | Heart Valve Technology | July 17, 2019
Abbott has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip heart valve repair...
Neovasc Tiara, Reducer Transcatheter Devices Featured at CSI Frankfurt 2019 Conference
News | Heart Valve Technology | July 09, 2019
Neovasc Inc. announced that its Tiara transcatheter mitral valve replacement (TMVR) device and its Neovasc Reducer...
Study Shows Inducing a Heart Attack Helps Valve Patients. This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates some of the tissue in the septum to allow for a larger LVOT area.

This image shows a left-ventricular outflow tract (LVOT) obstructed by an Edwards Sapien TAVR valve used for a valve-in-valve procedure. The arrow points to the small, crescent shaped dark area of the neo-LVOT, which did not allow enough blood to flow from the left ventricle into the aorta and the rest of the body. To prevent this issue, the procedure used by Henry Ford ablates (kills) some of the tissue in the cardiac septum to allow these valves to fit better and allow for an enlarged neo-LVOT for patients who otherwise could not receive this therapy. 

News | Heart Valve Technology | July 03, 2019
A study of a procedure developed at Henry Ford Health System shows inducing a heart attack in patients with heart...
CMS Finalizes Updates to Coverage Policy for Transcatheter Aortic Valve Replacement
Feature | Heart Valve Technology | June 24, 2019
The Centers for Medicare and Medicaid Services (CMS) recently finalized its decision to update the national coverage...
Overlay Init